Comparative Pharmacology
Head-to-head clinical analysis: IBU versus IBU TAB 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBU versus IBU TAB 200.
IBU vs IBU-TAB 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day. For OTC use: 200-400 mg every 4-6 hours; max 1200 mg/day.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; prolonged in neonates (30 hours) and elderly (up to 6 hours). No accumulation with recommended dosing due to short t½.
Clinical Note
moderateEribulin + Digoxin
"Eribulin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateEribulin + Digitoxin
"Eribulin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateEribulin + Deslanoside
"Eribulin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateEribulin + Acetyldigitoxin
"Eribulin may decrease the cardiotoxic activities of Acetyldigitoxin."
2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect.
Renal (90% as conjugated metabolites, 10% unchanged), biliary/fecal (minor, <5%)
Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)